Physician profile
Gary Roark
NPI 1003896531
$5,635.98
in general payments reported to CMS, 2019-2025
27 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $312 · 2021: $740 · 2022: $688 · 2023: $854 · 2024: $1,129 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.74 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $984.84 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $545.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $514.67 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $320.12 | 2022-2025 | Simponi, Stelara, Simponi Aria |
| Merck Sharp & Dohme LLC | $289.96 | 2020-2024 | Dificid, Zinplava |
| Ipsen Biopharmaceuticals, INC | $153.39 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $149.93 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $144.43 | 2021-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $122.02 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.73 | 2020-2025 | Xifaxan |
| Sirtex Medical INC | $107.64 | 2019 | |
| Gilead Sciences, INC. | $88.74 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $87.39 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $74.46 | 2023-2024 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $70.05 | 2020-2023 | |
| Redhill Biopharma INC. | $65.89 | 2020-2023 | Talicia |
| Braintree Laboratories, INC. | $38.66 | 2020-2021 | |
| Shionogi INC | $35.81 | 2019 | |
| Celgene Corporation | $34.28 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $32.14 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $31.06 | 2024-2025 | Omvoh |
| Organon LLC | $30.51 | 2023 | Renflexis |
| Genzyme Corporation | $20.25 | 2023 | |
| Neuraxis, INC. | $18.12 | 2025 | |
| Shire North American Group INC | $18.03 | 2019 | |
| Novo Nordisk INC | $13.87 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Roark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.